Public Policy

The bioscience industry is one of the most innovative and important economic drivers in the United States, accounting for over 1.6 million jobs.

Joe Damond, Senior Vice President of International Affairs at BIO, discusses the BIO report "2013 Policy Principles to Promote Biotechnology", the 4 key issues facing the global biotech industry from a policy perspective, and other issues of interest to the representatives from 65 countries who are in attendance at the 2013 BIO International Convention.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

Kimball Thomson, President & CEO of BioUtah discusses his organization and what makes Utah a good place for innovative industry growth.

Project BioShield seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear (CBRN) attacks.

Brent Del Monte, BIO’s Vice President of Federal Government Relations, discusses the 113th Congress and BIO’s 2013 legislative priorities.

The 2012 BIO International Convention featured a broad array of top-level speakers, addressing critical global challenges and the top issues in biotechnology. Hosted by the Biotechnology Industry Organization (BIO), the event drew 16,505 industry leaders from 65 countries.

President Obama signed the Jumpstart Our Business Startups (JOBS) Act into law on April 5, 2012. BIO advocated strongly for this new law, which includes several important policies designed to stimulate capital formation for growing businesses.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

At a time when the global economy struggles to recover from a severe recession and uncertainty remains regarding future economic growth, bioscience industry development is generating significant attention both globally and at home.

Successful multi-sector global health programs engage partners and policymakers early, communicate openly and frequently with relevant stakeholders, and empower and involve communities, according to a website relaunched this week, Case Studies for Global Health.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

John discusses the state of the industry and what he expects will be the top three issues highlighted at this year's BIO International Convention.  For more information on GEN, please visit

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

Letters, Testimony & Comments

October 29 2015
The Biotechnology Industry Organization (BIO) appreciates this opportunity to submit comments on the United States Patent and Trademark Office’s (USPTO) July 2015 Update on Subject Matter Eligibility (Guidance).
June 5 2015
BIO submitted a letter to members of the Senate Judiciary Committee regarding the Managers Amendment to PATENT Act.
June 4 2015
BIO submitted a letter to members of the Senate Judiciary Committee regarding the Managers Amendment to PATENT Act.
October 14 2014
The Biotechnology Industry Organization (BIO) welcomes the opportunity to provide comments to Public Consultation #65 published by the Board of Directors of the National Health Surveillance Agency on August 4, 2014 which proposes a new regulation defining the procedures and requirements for conducting clinical trials involving drugs in Brazil.
October 14 2014
The Biotechnology Industry Organization (BIO) welcomes the opportunity to provide comments to Public Consultation #8 published by the Brazilian Ministry of Health on August 14, 2014 which proposes a new regulation defining the guidelines and criteria for the submission, formation, monitoring and evaluation of PDP (Public-Private Productive Development Partnerships) projects.

Press Releases

October 26 2015
BIO applauds Reps. John Carney (D-DE), Sean Duffy (R-WI), Mike Quigley (D-IL), and Ander Crenshaw (R-FL) for introducing H.R. 3784, the SEC Small Business Advocate Act, which would ensure that growing companies have a strong, independent voice at the Securities and Exchange Commission (SEC).
September 16 2015
BIO President and CEO Jim Greenwood released the following statement today commending President Barack Obama for his nomination of Dr. Robert Califf as Commissioner of the Food and Drug Administration (FDA):
August 3 2015
BIO announced the appointment of Jeanne Haggerty as Senior Vice President of Federal Government Relations.
July 22 2015
BIO thanked Senate Finance Committee Chairman Orrin Hatch (R-Utah), Ranking Member Ron Wyden (D-Ore.) and other committee members for marking up legislation to extend critical tax incentives. The legislation would extend for two years the important Research & Development Tax Credit, the Second Generation Biofuel Producer Tax Credit, the Special Depreciation Allowance for Second Generation Biofuel Plant Property, and the Controlled Foreign Corporation Look-Through Rule.